DK1581812T3 - Sammensætninger og fremgangsmåde til diagnosticering og behandling af coloncancere - Google Patents
Sammensætninger og fremgangsmåde til diagnosticering og behandling af coloncancereInfo
- Publication number
- DK1581812T3 DK1581812T3 DK04700319T DK04700319T DK1581812T3 DK 1581812 T3 DK1581812 T3 DK 1581812T3 DK 04700319 T DK04700319 T DK 04700319T DK 04700319 T DK04700319 T DK 04700319T DK 1581812 T3 DK1581812 T3 DK 1581812T3
- Authority
- DK
- Denmark
- Prior art keywords
- colon cancer
- diagnosing
- compositions
- methods
- genes
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title abstract 6
- 208000029742 colonic neoplasm Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108700019961 Neoplasm Genes Proteins 0.000 abstract 2
- 102000048850 Neoplasm Genes Human genes 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/0061—The surface being organic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
- B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00709—Type of synthesis
- B01J2219/00711—Light-directed synthesis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Nanotechnology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Composite Materials (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43800003P | 2003-01-06 | 2003-01-06 | |
PCT/US2004/000035 WO2004061423A2 (en) | 2003-01-06 | 2004-01-06 | Compositions and methods for diagnosing and treating colon cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1581812T3 true DK1581812T3 (da) | 2008-10-20 |
Family
ID=32713264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04700319T DK1581812T3 (da) | 2003-01-06 | 2004-01-06 | Sammensætninger og fremgangsmåde til diagnosticering og behandling af coloncancere |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040265230A1 (da) |
EP (2) | EP1998177A3 (da) |
AT (1) | ATE401575T1 (da) |
AU (1) | AU2004203749A1 (da) |
CA (1) | CA2511907A1 (da) |
DE (1) | DE602004015064D1 (da) |
DK (1) | DK1581812T3 (da) |
ES (1) | ES2309485T3 (da) |
PT (1) | PT1581812E (da) |
SI (1) | SI1581812T1 (da) |
WO (1) | WO2004061423A2 (da) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
US7294471B2 (en) * | 2002-02-27 | 2007-11-13 | Cskeys, Llc | Method for purifying cancer-specific proliferating cell nuclear antigen |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
DE10339820A1 (de) * | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
WO2005095622A2 (en) * | 2004-03-26 | 2005-10-13 | Van Andel Research Institute | c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY |
WO2006088483A2 (en) * | 2004-06-16 | 2006-08-24 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the synthesis or expression of mmp-1 |
US20080254031A1 (en) * | 2004-09-09 | 2008-10-16 | Exonhit Therapeutics Sa | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis |
CN101095054A (zh) * | 2004-12-16 | 2007-12-26 | 株式会社英仙蛋白质科学 | 大肠癌和/或大肠息肉的诊断以及术后随访和复发的监测药物 |
WO2006078717A2 (en) * | 2005-01-19 | 2006-07-27 | Beth Israel Deaconess Medical Center | Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |
KR100681763B1 (ko) * | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
EA200702361A1 (ru) * | 2005-04-27 | 2008-04-28 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ |
US20080275652A1 (en) * | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
KR20130087639A (ko) * | 2005-07-27 | 2013-08-06 | 온코세라피 사이언스 가부시키가이샤 | 대장암 관련 유전자 tom34 |
EP2305811A1 (en) * | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
JP2009523009A (ja) * | 2005-09-21 | 2009-06-18 | バーンハム インスティトゥート フォー メディカル リサーチ | 結腸直腸癌を検出するための化合物及び方法 |
CA2624221A1 (en) * | 2005-10-24 | 2007-05-03 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
JP2009517479A (ja) * | 2005-11-29 | 2009-04-30 | ネバダ キャンサー インスティテュート | 骨髄異形成症候群(mds)に関連する増殖性疾患の治療および診断のためのsall4の標的化 |
US20080241110A1 (en) * | 2005-11-29 | 2008-10-02 | Nevada Cancer Institute | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) |
US7687062B2 (en) * | 2005-11-29 | 2010-03-30 | Rnl Bio Co. Ltd. | Method for diagnosing colon cancer |
US20070122854A1 (en) * | 2005-11-29 | 2007-05-31 | Rnl Bio Co. Ltd. | Method for diagnosing colon cancer |
EP1971359A2 (en) * | 2005-12-16 | 2008-09-24 | Electrophoretics Limited | Diagnosis and prognosis of colorectal cancer |
ES2277785B1 (es) * | 2005-12-21 | 2008-06-16 | Oryzon Genomics, S.A. | Metodo de analisis de expresion diferencial en cancer colorectal. |
US8258287B2 (en) * | 2005-12-21 | 2012-09-04 | Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) | Interfering RNAs targeting the morbillivirus nucleoprotein gene |
EP1884569A1 (en) | 2006-07-31 | 2008-02-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sensitization of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions |
EP4082551A1 (en) | 2006-08-08 | 2022-11-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Structure and use of 5' phosphate oligonucleotides |
WO2008020653A1 (en) * | 2006-08-18 | 2008-02-21 | Oncotherapy Science, Inc. | Use of holliday junction-recognizing protein related to cancer |
TW200831673A (en) * | 2006-12-13 | 2008-08-01 | Oncotherapy Science Inc | TTK as tumor marker and therapeutic target for lung cancer |
WO2008088836A2 (en) * | 2007-01-16 | 2008-07-24 | The Burnham Institute For Medical Research | Compositions and methods for treatment of colorectal cancer |
WO2008151021A1 (en) * | 2007-06-01 | 2008-12-11 | Nevada Cancer Institute | Isolation and growth of stem cells from hemangiomas |
US20080299077A1 (en) * | 2007-06-01 | 2008-12-04 | Nevada Cancer Institute | Isolation and growth of stem cells from hemangiomas |
TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
EP3895737A1 (en) * | 2007-06-29 | 2021-10-20 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Method of fixing and expressing physiologically active substance |
AU2014201635B2 (en) * | 2007-07-15 | 2016-06-23 | Technion Research & Development Foundation Ltd. | Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
IL184627A0 (en) * | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
US7994276B2 (en) * | 2007-07-27 | 2011-08-09 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
DK2185937T4 (da) | 2007-09-07 | 2014-10-20 | Univ Zuerich | Fremgangsmåde til at bestemme sepsis hos mennesker |
CA2705509A1 (en) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-gpr49 antibody |
US20090233294A1 (en) * | 2008-01-29 | 2009-09-17 | Elias Georges | Uhrf1 directed diagnostics for neoplastic disease |
EP2297323A1 (en) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
KR101007574B1 (ko) | 2009-07-28 | 2011-01-14 | 한국생명공학연구원 | 대장암 과발현 유전자를 이용한 대장암 진단 마커 |
KR100958086B1 (ko) | 2009-07-28 | 2010-05-14 | 한국생명공학연구원 | 대장암 과발현 유전자를 이용한 대장암 진단 마커 |
EP2467393A4 (en) * | 2009-08-19 | 2013-01-23 | Blood Systems Inc | NEW SPECIES OF ASTROVIRUS |
AU2010284036B2 (en) | 2009-08-21 | 2014-12-18 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
US20130023578A1 (en) * | 2009-12-31 | 2013-01-24 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of c-Met expression and anticancer composition containing the same |
CN103370080A (zh) | 2010-02-04 | 2013-10-23 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
US9422598B2 (en) | 2010-06-04 | 2016-08-23 | Biomerieux | Method and kit for the prognosis of colorectal cancer |
DK2646546T3 (da) | 2010-12-02 | 2018-08-06 | Oncotherapy Science Inc | Tomm34-peptider og vacciner, der indeholder disse |
WO2012087144A2 (en) * | 2010-12-23 | 2012-06-28 | Agendia N.V. | Methods and means for molecular classification of colorectal cancers |
EP2683825B1 (en) * | 2011-03-11 | 2017-01-04 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
WO2012129758A1 (en) * | 2011-03-25 | 2012-10-04 | Biomerieux | Method and kit for determining in vitro probability for individual to suffer from colorectal cancer |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
WO2013043128A1 (en) | 2011-09-20 | 2013-03-28 | Brigham And Women's Hospital | Sall4 and uses thereof |
GB201207998D0 (en) * | 2012-05-08 | 2012-06-20 | Univ Cardiff | A screening method for the detection of clostridium difficle |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
WO2014109780A1 (en) * | 2013-01-11 | 2014-07-17 | Phaserx, Inc. | Rna targeted to c-met |
US9862943B1 (en) * | 2013-06-27 | 2018-01-09 | California Institute Of Technology | Long noncoding RNAs and cell reprogramming and differentiation |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
WO2015057727A1 (en) * | 2013-10-14 | 2015-04-23 | Isis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
WO2015066212A2 (en) * | 2013-10-31 | 2015-05-07 | University Of Hawaii | Calpain inhibitors for treatment of inflammatory bowel disease and colorectal cancer |
WO2016083624A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for inhibiting the expression of edn1 |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
MA48487B1 (fr) | 2014-12-23 | 2021-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
PT109454A (pt) * | 2016-06-14 | 2017-12-14 | Phyzat Biopharmaceuticals Lda | Ácidos nucleicos de interferência e composições que os compreendem |
EP3388520A1 (en) * | 2017-04-11 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof |
WO2018224731A1 (en) * | 2017-06-05 | 2018-12-13 | Ls Cancerdiag Oy | A method for determining whether a subject is at risk to develop cancer and tools related thereto |
EP3737946A4 (en) | 2018-01-12 | 2021-11-03 | Celgene Corporation | METHOD OF SCREENING CEREBLON MODIFYING COMPOUNDS |
US20240141340A1 (en) * | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419446A (en) * | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4489710A (en) * | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
JP2547714B2 (ja) * | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | オリゴヌクレオチド治療剤及びその製法 |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4798885A (en) * | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
ZA874681B (en) * | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5266464A (en) | 1988-02-10 | 1993-11-30 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US4980281A (en) * | 1988-02-10 | 1990-12-25 | Housey Gerard M | Method of screening for protein inhibitors and activators |
US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
KR920007887B1 (ko) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | 내연기관의 배기가스 정화장치 |
KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9509757D0 (en) * | 1995-05-13 | 1995-07-05 | Ilford Ltd | Toning of photographic print material |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
US5965403A (en) * | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
DE69941330D1 (de) * | 1998-03-26 | 2009-10-08 | Univ R | Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region |
AU2001236777A1 (en) * | 2000-02-08 | 2001-08-20 | Millennium Pharmaceuticals, Inc. | 39406 protein, a seven transmembrane protein |
US20030027323A1 (en) * | 2000-09-27 | 2003-02-06 | Feder John N. | Novel human G-protein coupled receptor, HGPRBMY5, expressed highly in brain and ovarian tissues |
WO2002059376A1 (en) * | 2001-01-23 | 2002-08-01 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer |
US20030232350A1 (en) * | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
EP1380644A1 (en) * | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
US20060134109A1 (en) * | 2002-09-09 | 2006-06-22 | Nura Inc. | G protein coupled receptors and uses thereof |
US20060111314A1 (en) * | 2002-09-30 | 2006-05-25 | Oncotheraphy Science, Inc. | Method for treating or preventing metastasis of colorectal cancers |
-
2004
- 2004-01-06 EP EP08011895A patent/EP1998177A3/en not_active Withdrawn
- 2004-01-06 ES ES04700319T patent/ES2309485T3/es not_active Expired - Lifetime
- 2004-01-06 DK DK04700319T patent/DK1581812T3/da active
- 2004-01-06 AT AT04700319T patent/ATE401575T1/de not_active IP Right Cessation
- 2004-01-06 PT PT04700319T patent/PT1581812E/pt unknown
- 2004-01-06 CA CA002511907A patent/CA2511907A1/en not_active Abandoned
- 2004-01-06 SI SI200430834T patent/SI1581812T1/sl unknown
- 2004-01-06 AU AU2004203749A patent/AU2004203749A1/en not_active Withdrawn
- 2004-01-06 DE DE602004015064T patent/DE602004015064D1/de not_active Expired - Lifetime
- 2004-01-06 WO PCT/US2004/000035 patent/WO2004061423A2/en active Search and Examination
- 2004-01-06 US US10/751,736 patent/US20040265230A1/en not_active Abandoned
- 2004-01-06 EP EP04700319A patent/EP1581812B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1998177A3 (en) | 2009-02-18 |
AU2004203749A1 (en) | 2004-07-22 |
WO2004061423A2 (en) | 2004-07-22 |
EP1998177A2 (en) | 2008-12-03 |
SI1581812T1 (sl) | 2008-10-31 |
US20040265230A1 (en) | 2004-12-30 |
EP1581812B1 (en) | 2008-07-16 |
PT1581812E (pt) | 2008-09-22 |
ATE401575T1 (de) | 2008-08-15 |
EP1581812A2 (en) | 2005-10-05 |
CA2511907A1 (en) | 2004-07-22 |
DE602004015064D1 (de) | 2008-08-28 |
ES2309485T3 (es) | 2008-12-16 |
WO2004061423A3 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1581812T3 (da) | Sammensætninger og fremgangsmåde til diagnosticering og behandling af coloncancere | |
ATE547102T1 (de) | Carbolin-derivate zur behandlung von krebs | |
WO2004070062A3 (en) | Compositions and methods for diagnosing and treating cancers | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
IL229136A0 (en) | mek inhibitors and methods of using them | |
BRPI0514017A (pt) | indazóis úteis no tratamento de doenças cardiovasculares | |
MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
BR0315689A (pt) | Alvo para terapia de dano cognitivo | |
NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
ECSP066986A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
UA85559C2 (en) | Aminobenzophenone compounds | |
WO2005085861A3 (en) | Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer | |
BRPI0416268A (pt) | composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla | |
DK1560812T3 (da) | Aminocyclohexyletherforbindelser og anvendelser deraf | |
NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
MXPA05005314A (es) | Compuestos de lapacona novedosos y metodos de uso de los mismos. | |
WO2004058158A3 (en) | Treatment of metastatic cancer with the b-subunit of shiga toxin | |
WO2004029287A3 (en) | Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer | |
ATE435647T1 (de) | Rutheniumkomplexe zur krebsbehandlung | |
ATE445408T1 (de) | Verwendung von prolactin in der prophylaktischen krebstherapie | |
NO20055650L (no) | Ruteinum (II)-komplekser for behandling av tumorer | |
DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
ATE406375T1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate | |
EP1417968A3 (en) | Antitumour compositions containing propolis and resveratrol | |
ATE411313T1 (de) | Neue makrocyclen zur behandlung von krebserkrankungen |